A pproximately 6.5 million adults in the United States have heart failure (HF), representing a major cause of morbidity and mortality (1). S E P T E M B E R 2 0 1 9 : 5 9 2 -5 exchanger, lowering of cytosolic Na(þ) and vasodilation. Diabetologia 2018;61:722-6.
HF is traditionally divided into 2 subtypes, HF with preserved ejection (HFpEF) and HF with reduced ejection fraction (HFrEF), with each accounting for about 50% of HF cases. Although HFpEF and HFrEF can display similar clinical presentations during acute HF exacerbations, they are often associated with different risk factors, pathophysiological processes, and responses to therapy (2) . Many therapies with unequivocal benefit in HFrEF have failed to show efficacy for HFpEF. This is, in part, why the recent findings of EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes) have generated tremendous enthusiasm.
EMPA-REG OUTCOME was a randomized, doubleblind, placebo-controlled trial of 7,020 patients with type 2 diabetes mellitus, and it demonstrated that the primary endpoint, a composite of myocardial infarction, stroke, and cardiovascular death, was significantly reduced (hazard ratio [ (5, 6) .
Empagliflozin is one of a family of inhibitors that target the sodium (Na þ )-glucose cotransporter-2 (SGLT2). SGLTs are transmembrane proteins that facilitate entry of glucose into cells by making use of the Na þ gradient maintained by sodium-potassium adenosine triphosphatase (7) . SGLT2 inhibitors were developed as a therapeutic treatment for diabetes because of their inhibition of glucose reabsorption in the proximal tubules of the kidneys, increasing glucose excretion. In EMPA-REG OUTCOME, the adjusted mean reduction in glycated hemoglobin relative to placebo was modest and gradually shrunk over the course of the study (3). These findings, in part, have led to an increasing recognition of potential pleiotropic effects of SGLT2 inhibitors beyond simply hypoglycemic effects. Although the molecular mechanisms are not fully understood, the effects of SGLT2 inhibitors are postulated to be multifactorial, including hemodynamics involving blood pressure reduction and diuresis, loss of body weight, and reductions in the renin-angiotensin-aldosterone system (7, 8) . SGLT2 inhibitors have also demonstrated some adverse reactions; canagliflozin is associated with a doubling of the risk for lower-limb amputation and with increased risk of fractures, and empagliflozin is associated with increased genital infections (3, 9) .
In the paper by Juni et al. (10) This new study also raises interesting questions as to whether the molecular mechanisms that govern the therapeutic effects of this emerging class of agents are specific to the inhibition of SGLT2. Though SGLT1 mRNA is abundantly expressed in the human heart and in other tissues, SGLT2, the selective target of empagliflozin, has been largely identified in skeletal muscle and kidney but not in heart (12, 13) . Some studies have indicated that SGLT2 may be expressed at low levels in endothelial cells (14, 15) , but the au- 
